Recent data from clinical studies of Tregalizumab, formerly known as BT-061, present insight into its anticipated benefit for managing multiple autoimmune conditions – particularly, anterior uveitis. Phase three https://opensocialfactory.com/story26983532/tregalizumab-a-deep-analysis-into-bt-061-s-therapeutic-studies